https://doi.org/10.4081/uij.2012.e9

Persistence and adherence of solifenacin treatment for Japanese women with overactive bladder

Vol. 26 No. 1 (2012)
Submitted: 5 March 2012
Accepted: 4 October 2012
Published: 11 October 2012
adherence, overactive bladder, persistence, solifenacin.
Abstract Views: 562
PDF: 223
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Minoru Kobayashi
minoruk@jichi.ac.jp
Department of Urology, Jichi Medical University, Tochigi, Japan.
Akinori Nukui
Department of Urology, Jichi Medical University, Tochigi, Japan.
Shinsuke Kurokawa
Department of Urology, Jichi Medical University, Tochigi, Japan.
Tatsuo Morita
Department of Urology, Jichi Medical University, Tochigi, Japan.
Persistence and adherence of overactive bladder (OAB) medication have reported to be generally lower in real-world setting as compared with those in clinical trials. However, this information in Japanese population has not been well addressed. Medical records were reviewed for solifenacin as an initial treatment for 172 women with OAB symptom to examine medication persistence, switching, adherence, and the reasons for discontinuation. The associations between persistence and the reasons for discontinuation as well as concomitant conditions regarded as OAB-related risk factors were assessed. The 6-month and 1-year persistence rate of solifenacin were 39.8% and 27.8%, respectively. Consequently, 121 patients (70.3%) discontinued solifenacin, of whom 18 (14.9%) patients switched to other OAB drugs and 9 (7.4%) patients restarted solifenacin. Thus, the adherence rate was 66.8%. More women discontinued solifenacin owing to symptom resolution (41.3%) rather than unfavorable outcomes such as adverse effects (12.4%) and lack of efficacy (21.5%). However, such reason for discontinuation was not the determinant of persistence of solifenacin. There was a non-significant trend towards higher persistence for those with OAB-related risk factors. Japanese women discontinued solofenacin treatment with various reasons in real-world practice, resulting in much lower persistence as compared with clinical trials. A further prospective study in a larger cohort of patients is awaited to better assess their persistence and adherence and understand exact efficacy and tolerability of antimuscarinics for Japanese patients with OAB.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

none

How to Cite

Kobayashi, M., Nukui, A., Kurokawa, S., & Morita, T. (2012). Persistence and adherence of solifenacin treatment for Japanese women with overactive bladder. Urogynaecologia, 26(1), e9. https://doi.org/10.4081/uij.2012.e9

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.